PDL BioPharma — FY2017 Earnings Presentation
15 slides from PDL BioPharma's earnings presentation, Mar 8, 2018
Slide 1: Fourth Quarter/Year End 2017 Financial Results Conference Call
PDL Fourth Quarter/Year End 2017 Financial Results Conference Call March 8, 2018
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements, including PDL's expectations with respectto its future royalty revenues, expenses, net income, and cash provided by operating activities. Each of these forward-looking statements involves risks and uncertainties. Actua
Slide 3: Building Value Through Investments
Building Value Through Investments o Focused on growth in order to continue value creation for shareholders. o Pleased with PDL’s achievements to replace the revenues from the expired Queen et al patents. = Strategic decisions have enabled income generating assets to fuel PDL’s business of today. =
Slide 4: Royalty Investments
Royalty Investments o Royalties relating to Depomed have far exceeded our expectations. = Investment made in October 2013 for $240.5 million. = Have accumulated $308.5 million through December 2017. = Glumetza and its authorized generic account for bulk of returns. = Expect other Depomed products, i
Slide 5: Noden Background
Noden Background o Noden Pharma = Platform upon which to build a pharmaceutical company. = PDL now owns 100% of Noden companies. = Noden already has two products on the market—both indicated for hypertension. —Tekturna® and Tekturna HCT®, as they are known in the US, and Rasilez® and Rasilez HCT®, a
Slide 6: Noden: Building Profitable Growth
Noden: Building Profitable Growth o Reported revenues on the Noden products for Q417 of $25.1 million. > $14.5 million from US sales and $10.6 million from ROW. o In November 2017, Noden assumed commercialization of Rasilez and Rasilez HCT in Switzerland and the EU as we transitioned away from profi
Slide 7: Tekturna & Tekturna HCT
Tekturna & Tekturna HCT ly Revenu $in millions $9,000 oe $7.193 STARS $7,464 97-633. 344 $6.943 $7,000 -¢6-447 $6.565 $6.491 $6474 sei $5.73 $5.910 $5.847 $5.000 $4,000 $3,000 $2,000 $1.000 $ Jan-17 Feb-17 Mar-17 Apr-17 May-17 Jun-17 Jul-17 Aug-17 Sep-17 Oct-17 Nov-17 Dec-17 Jan-18 was PDL
Slide 8: Executing Targeted Patient-Type Strategy
Executing Targeted Patient-Type Strategy ACE/ ARB Intolerant: SWITCH CCB Notat Goal: ADD
Slide 9: Tekturna & Tekturna HCT Prescriptions
Tekturna & Tekturna HCT Prescriptions Tekturna Prescription Data - All Strengths 5000 4500 SO SS SS LSS HSH So OO SS Hg gH se gh” gh” ge Bg PH HP” og Hh gH hh” oO” S” oh A Mh QP KP KP Kh aK AHH Kh oh XP XP? XH BP rr rt EE MEI OE EE 3 FM HW Source: IMS Xponent weekly data PDL
Slide 10: Continued Progress at LENSAR
Continued Progress at LENSAR o Achieved quarterly revenue record of $7.5 million. o Recently added two highly acclaimed board members. = William “Bill” J. Link, Ph.D. » Richard L. Lindstrom, M.D. o Acquired laser business unit of Precision Eye Services (PES). = Consolidates LENSAR’s customer base fo
Slide 11: Termination of Proposal to Acquire Neos
"1 Termination of Proposal to Acquire Neos In June 2017, PDL made a verbal all cash proposal to acquire all shares of Neos for $10/share, including the possibility to increase the offer with limited due diligence, which was rejected by the Neos Board several days later as not compelling or specific
Slide 12: Building Value Through Investments
Building Value Through Investments A-10N tas am avhev ares awe 9T-10N or-das sramr or-heve ore over ST-10N stds stam sth stew sever PDL's Book Value Per Share ld iS = nN o / G a2 = G rs) o a HON tos eran whew tre aoe eI-10N exdas st re 9 oO fe} 2 a] o a % o £ 3) i= o = o > x [e} fe} io yn eal a a Su
Slide 13: Fourth Quarter 2017 Financials
Fourth Quarter 2017 Financials Three Months Ended ‘Twelve Months Ended December 31. December 31. (In thousands, except per share amounts) 207 2016 2017 2016 Royalties from Queen et a. patents $453 § 15513 § 36415 _§ 166158 Royalty rights - change in fair value 30.103 28,068 162.327 16.196 Interest r
Slide 14: Fourth Quarter 2017 Financials
Fourth Quarter 2017 Financials Condensed consolidated balance sheet (unaudited) December 31, Cash, cash equivalents and investments u Total notes receivable Total royalty rights - at fair value Total assets Convertible notes payable Total stockholders's equity December 31, 2017 2016 $ 532,114 $ 242,
Slide 15: Question and Answer Session
PDL Question and Answer Session